Tenax Therapeutics ($TENX) Insider Trading & Smart Money Activity

Tenax Therapeutics, Inc. · Biotechnology · Latest filing Jun 24, 2026

Tenax Therapeutics, Inc. ($TENX) has 4 analyst ratings on file.

Insider buyers (12 mo)

0

Insider sellers (12 mo)

0

Net insider $ (12 mo)

$0

Congress trades (12 mo)

0

13F moves on file

0

Analyst ratings on file

4

TENX insider buying and selling by quarter

Quarter	Insider buys	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0	0 / 0	0 / 0
Q2 2026	0	0	0 / 0	0 / 0
Q3 2026	0	0	0 / 0	0 / 0
Q4 2026	0	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All TENX insider, congress, 13F and analyst activity

All Analysts

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Jun 24, 2026	Analyst	Cantor Fitzgerald	Reiterates to buy		PT $35		+2.8%	+12.4%			Read
Jun 22, 2026	Analyst	Guggenheim	Reiterates to buy		PT $40		+10.2%	+20.7%			Read
Jun 22, 2026	Analyst	Chardan Capital	Reiterates to buy		PT $27		+10.2%	+20.7%			Read
Jun 12, 2026	Analyst	Piper Sandler	Reiterates to buy		PT $50		+6.7%	+39.2%			Read

1W / 1M / 6M = how TENX moved from the trade or filing date.

Analyst ratings on TENX

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jun 24, 2026	Cantor Fitzgerald	Reiterates	buy	$35	+2.8%	+12.4%		Read
Jun 22, 2026	Guggenheim	Reiterates	buy	$40	+10.2%	+20.7%		Read
Jun 22, 2026	Chardan Capital	Reiterates	buy	$27	+10.2%	+20.7%		Read
Jun 12, 2026	Piper Sandler	Reiterates	buy	$50	+6.7%	+39.2%		Read

Other biotechnology stocks

• $APLM
• $GOSS
• $ATHE
• $PLRX
• $SPRO
• $BOLD
• $GANX
• $FBIO

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.